Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-1358 Monotherapy in Patients With Metastatic or Locally Advanced Breast Cancer.

Next Previous
Trial Profile

A Single-arm, Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-1358 Monotherapy in Patients With Metastatic or Locally Advanced Breast Cancer.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HRS 1358 (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors Shandong Suncadia Medicine

Most Recent Events

  • 17 Mar 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2025.
  • 07 Aug 2024 Planned primary completion date changed from 30 Jun 2024 to 1 Dec 2024.
  • 27 Feb 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top